RxDoctor Payments DataLook up a doctor →

Robert Kaplan, DO

Family Medicine · Las Vegas, NVNPI 1124101035

Payments from drug & device makers

$1,733,699in general payments, 2019–2025

Across 413 payments — averaging $4197.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$993K
  • Pfizer$541K
  • Noven Pharmaceuticals, Inc.$85K
  • Phathom Pharmaceuticals, Inc.$58K
  • AstraZeneca$31K
  • Braintree Laboratories, Inc.$13K
  • plus $13K from 37 others

What the payments were for

  • Speaking & faculty fees$4005%
  • Food & beverage$7,27895%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,733,699 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$131,950
Medicare patients
174
Services billed
1,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$138,712
OzempicSemaglutide40$42,005
EliquisApixaban30$38,757
VascepaIcosapent Ethyl40$34,228
KerendiaFinerenone19$27,914
JardianceEmpagliflozin18$26,648
RybelsusSemaglutide14$26,126
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,049
Soliqua 100-33Insulin Glargine/Lixisenatide12$16,924
SymbicortBudesonide/Formoterol Fumarate16$9,777
EntrestoSacubitril/Valsartan11$5,887
Icosapent Ethyl11$4,268
Humalog Kwikpen U-100Insulin Lispro11$3,607
Atorvastatin Calcium346$2,298
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen96$1,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$383$138,712111 claims
Novo NordiskOzempic, Rybelsus$415$68,13154 claims
PfizerEliquis$540,557$38,75730 claims
AstraZenecaBreztri Aerosphere, Symbicort$31,496$28,82642 claims
BayerKerendia$295$27,91419 claims
Boehringer IngelheimJardiance$175$26,64818 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$454$16,92412 claims
NovartisEntresto$992,837$5,88711 claims
AbbVieSynthroid$1,028$76117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →